Privately-held clinical-stage immunotherapy company, Vaccinex, Inc., recently announced that it has signed a multi-target antibody discovery deal with Five Prime Therapeutics.
Vaccinex said that it has entered into a multi-target collaboration agreement with Five Prime to utilize Vaccinex’s ActivMab antibody discovery platform for the discovery of monoclonal antibodies against novel targets identified by Five Prime’s proprietary discovery platform.
The companies did not disclose financial details of the agreement.
Vaccinex is focused on the discovery and development of human therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases, including multiple sclerosis (MS) and Huntington Disease. The company uses its ActivMab Antibody Discovery Technology for rapid mammalian cell-based antibody selection to build its pipeline of antibodies. The platform combines the advantages of both panning and cell sorting to enable efficient identification of high-affinity, fully human antibodies.
Under the terms of the agreement, Five Prime will gain exclusive, worldwide rights to develop and commercialized Vaccinex-discovered monoclonal antibodies. In exchange, Vaccinex will receive upfront fees and research, support and performance payments. Additionally, Vaccinex is eligible to receive milestone payments and low single-digit royalties on future net sales of any resulting products commercialized by Five Prime.
“We are very pleased to enter into this collaboration with Five Prime, a company that has developed one of the most comprehensive libraries of potential targets for protein therapies for immuno-oncology and other applications,” said Maurice Zauderer, PhD, President and Chief Executive Officer of Vaccinex. “Innovation has long been the driving force in value creation by biotech companies, and we look forward to novel products emerging from this combination of Five Prime’s discovery and development capabilities and Vaccinex’s platform for the selection of high quality antibodies.”
Source: Vaccinex, Inc.
Last updated: 3/20/15; 11:05am EST